24 June 2025 - Just two months after German pharma Boehringer Ingelheim secured long-delayed reimbursement for Ofev in Korea, generics are already muscling in.
Yungjin Pharm and Ildong Pharmaceutical are now poised to enter the fibrotic lung disease market with their nintedanib tablets after the Ministry of Health and Welfare included both drugs -- Nintebro and Cuninta -- in a draft update to the country’s reimbursement guidelines released last Thursday.